Relay reports Q3 2026 financial results; expects ReDiscover-2 trial enrollment complete in mid-2027
Relay Therapeutics reported $849 million in cash and announced ongoing Phase 3 trial enrollment progress for breast cancer. The company also provided an update regarding an upcoming ASH conference presentation and the hiring of a new executive to lead commercial preparations.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed